Browsing by Author "Córdova Delgado, Miguel"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Differentially Expressed Genes and Signaling Pathways Potentially Involved in Primary Resistance to Chemo-Immunotherapy in Advanced-Stage Gastric Cancer Patients
    (MDPI, 2023) Pinto, Mauricio P.; Bravo, María Loreto; Córdova Delgado, Miguel; Hill, Charlotte N.; Muñoz Medel, Matías; Retamal, Ignacio N.; Fernández, M. Fernanda; Sánchez, Carolina; Sáez, Mauricio A.; Morales Pison, Sebastián; García Bloj, Benjamín; Garrido, Marcelo; Latapiat, Verónica; Martín, Alberto J.M.; Fernández Ramírez, Ricardo; Owen Gareth Ivor
    Recently, the combination of chemotherapy plus nivolumab (chemo-immunotherapy) has become the standard of care for advanced-stage gastric cancer (GC) patients. However, despite its efficacy, up to 40% of patients do not respond to these treatments. Our study sought to identify variations in gene expression associated with primary resistance to chemo-immunotherapy. Diagnostic endoscopic biopsies were retrospectively obtained from advanced GC patients previously categorized as responders (R) or non-responders (NR). Thirty-four tumor biopsies (R: n = 16, NR: n = 18) were analyzed by 3? massive analysis of cDNA ends (3?MACE). We found >30 differentially expressed genes between R and NRs. Subsequent pathway enrichment analyses demonstrated that angiogenesis and the Wnt-?-catenin signaling pathway were enriched in NRs. Concomitantly, we performed next generation sequencing (NGS) analyses in a subset of four NR patients that confirmed alterations in genes that belonged to the Wnt/?-catenin and the phosphoinositide 3-kinase (PI3K) pathways. We speculate that angiogenesis, the Wnt, and the PI3K pathways might offer actionable targets. We also discuss therapeutic alternatives for chemo-immunotherapy-resistant advanced-stage GC patients.
  • Thumbnail Image
    Item
    Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy
    (2022) Acevedo Claros, Francisco Nicolás; Walbaum García, Benjamín Vicente; Muñiz Muñoz, María Sabrina; Petric Guajardo, Militza Paulina; Martínez, Raúl; Guerra, Constanza; Navarro, Marisel; Córdova Delgado, Miguel; Pinto, Mauricio P.; Sánchez Rojel, César Giovanni
    Pathological complete response (pCR) after neoadjuvant chemotherapy (NCT) is associated with good long-term prognosis in breast cancer (BC) patients. However, some patients still recur and eventually die from this disease. For years, clinical stage at diagnosis has been consistently linked to recurrence and survival in the pCR setting. Herein, we aimed to identify other potential predictors of recurrence and survival in patients that achieved pCR. We performed a retrospective analysis of patients diagnosed between 2011 and 2020 in our center. We calculated overall survival (OS), invasive disease-free survival (IDFS), distant disease-free survival (DDFS), and BC-specific survival (BCSS). Among the 241 patients included into our study 36% were obese (Body Mass Index (BMI) > 29.9 kg/m2) and 47% were stage III. Multivariate analysis confirmed that obesity was a significant risk factor associated with early recurrence and poorer survival in these patients. In summary, obesity and clinical stage predict early recurrence and poorer survival in patients that achieved pCR after NCT. Pending further investigation and based on our findings we speculate that weight management could be beneficial for this subset of patients. To our knowledge, this is the first Latin American report linking obesity and recurrence within this setting.